Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript Summary
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript Summary
The average selling price for Guardant360 reached $3,000 per test, reflecting strong reimbursement rates and effective cash collection.The following is a summary of the Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript:
以下是Guardant Health, Inc. (GH)第三季度2024年業績會的摘要:
Financial Performance:
財務表現:
Guardant Health reported a significant revenue increase in Q3 2024, reaching $191.5 million, a 34% growth.
Precision oncology contributed prominently to this growth, with revenue increasing by 35% to $180.6 million.
The average selling price for Guardant360 reached $3,000 per test, reflecting strong reimbursement rates and effective cash collection.
Biopharma revenue also grew by 34% driven by a 40% increase in test volume to 10,500 tests.
Guardant Health在2024年第三季度報告了顯著的營業收入增長，達到19150萬美元，增長了34%。
精準腫瘤學在這一增長中發揮了重要作用，營業收入增長了35%，達到18060萬美元。
Guardant360的平均銷售價格達到每項3000美元，反映了強勁的報銷率和有效的現金收款。
生物製藥業務的營業收入也增長了34%，受到測試量增加40%至10500個測試的推動。
Business Progress:
業務進展:
Guardant Health launched the upgraded Guardant360 LVT and smart liquid biopsy platform, which expands the number of genes tested and improves sensitivity.
Initiated a partnership with Policlinico Gemelli in Rome for onsite processing of Guardant360 CDx tests.
Published results from the SCRUM-Japan GOZILA study in Nature Medicine, underscoring the clinical utility of Guardant360 in advanced gastrointestinal cancer.
Guardant Shield received FDA approval for colorectal cancer screening, with a successful commercial launch following shortly thereafter.
Achieved positive free cash flow in the therapy selection business during Q3.
Guardant Health推出了升級版Guardant360 LVt和智能液體活檢平台，擴大了測試基因數量，並提高了靈敏度。
與羅馬Policlinico Gemelli合作，現場處理Guardant360 CDx檢測。
在《自然醫學》雜誌上發表了SCRUm-Japan GOZILA研究的結果，強調了Guardant360在日本進階胃腸癌臨床應用的重要性。
Guardant Shield獲得FDA批准用於結直腸癌篩查，隨後成功商業化推出。
Q3期間在治療選擇業務中取得正面的自由現金流。
Opportunities:
機會：
Guardant Health's advancements in the therapy selection business, particularly with Guardant360 and TissueNext, continue to open broader market opportunities and higher reimbursement potentials, especially with new Medicare rate increases.
The FDA approval and subsequent Medicare coverage for Shield provide significant market expansion opportunities in colorectal cancer screening.
在治療選擇業務中，Guardant Health在Guardant360和TissueNext方面的進展繼續拓展更廣泛的市場機會和更高的報銷潛力，尤其是隨着新的醫療保險費率增加。
Shield獲得FDA批准和隨後的醫療保險覆蓋爲結直腸癌篩查提供了重要的市場擴張機會。
Risks:
風險：
Incremental growth in AI services like Guardant360 will be gradual, indicating a steady yet slow increase in adoption rate for the upgraded testing services.
人工智能服務的增長，如guardant health 360，將是漸進式的，表明升級測試服務的採納率將穩步但緩慢地增加。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
